"The State Street SPDR S&P Biotech ETF (XBI) started in January 2021 at $175, dropped to $63 in 2023, and has since fluctuated significantly, currently around $128."
"Analysts Salveen Richter and Jared Holz express a bullish sentiment for the biotech industry in 2026, citing strong market fundamentals and potential growth opportunities."
"XBI has gained +58% in the past year, with an average daily volume of 10 million shares, making it one of the largest Healthcare sector ETFs."
"The equal-weighted structure of XBI allows for a stronger tilt towards smaller companies, which may benefit from breakthroughs and FDA approvals."
The biotech industry has experienced significant fluctuations over the past five years, with the State Street SPDR S&P Biotech ETF (XBI) seeing a drop of over 50% from its peak. Currently, XBI has gained 58% in the past year and has a strong buy consensus rating. Analysts express optimism for the biotech sector in 2026, citing factors such as interest rates and market dynamics. XBI's unique equal-weighted structure allows for greater exposure to smaller companies, enhancing its potential for growth.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]